• OPEN AN ACCOUNT
Indian Indices
Sensex
73,606.75 482.92
( 0.66%)
Global Indices
Nasdaq
52,230.09 -658.89
(-1.25%)
Dow Jones
7,644.13 -40.30
(-0.52%)
Hang Seng
62,433.43 -259.73
(-0.41%)
Nikkei 225
10,766.40 76.04
(0.71%)
Forex
USD-INR
94.61 0.10
(0.11%)
EUR-INR
106.18 0.08
(0.07%)
GBP-INR
126.70 0.19
(0.15%)
JPY-INR
0.60 0.00
(0.70%)

EQUITY - MARKET SCREENER

Concord Biotech Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
543960
INE338H01029
193.0629905
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
CONCORDBIO
45.21
12855.76
EPS(TTM)
Face Value()
Div & Yield %
27.18
1
0.61
 

Tilak Ventures standalone net profit rises 151.63% in the March 2026 quarter
May 21,2026
Net profit of Tilak Ventures rose 151.63% to Rs 3.85 crore in the quarter ended March 2026 as against Rs 1.53 crore during the previous quarter ended March 2025. Sales rose 120.09% to Rs 14.02 crore in the quarter ended March 2026 as against Rs 6.37 crore during the previous quarter ended March 2025.

For the full year,net profit rose 53.43% to Rs 9.62 crore in the year ended March 2026 as against Rs 6.27 crore during the previous year ended March 2025. Sales rose 43.67% to Rs 30.43 crore in the year ended March 2026 as against Rs 21.18 crore during the previous year ended March 2025.

ParticularsQuarter EndedYear Ended
Mar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var.
Sales14.026.37 120 30.4321.18 44
OPM %49.0018.52 -27.6717.33 -
PBDT5.742.43 136 13.698.53 60
PBT5.742.43 136 13.688.52 61
NP3.851.53 152 9.626.27 53